期刊文献+

含乙酰氧肟酸配体的席夫碱钒配合物的合成、结构及其抑制幽门螺旋杆菌脲酶研究(英文) 被引量:8

Synthesis, Structures and Helicobacter Pylori Urease Inhibition of Schiff Base Vanadium Complexes Containing Acetohydroxamate Ligands
在线阅读 下载PDF
导出
摘要 本文合成了2个新的含乙酰氧肟酸配体的席夫碱钒配合物,[VⅢL1(HAHA)](1)和[VⅤOL2(AHA)](2),其中L1为N,N′-二(5-甲基水杨基)乙烷-1,2-二胺的二价阴离子,L2为2-{[2-(2-羟乙基氨基)乙亚胺基]甲基}-6-甲基苯酚的一价阴离子,HAHA和AHA分别为乙酰氧肟酸的一价和二价阴离子,通过物理-化学方法以及单晶X-射线衍射表征了它们的结构。在每个化合物中,V原子都采取八面体配位构型。本文还研究了配合物的热稳定性以及其对幽门螺旋杆菌脲酶的抑制活性。在浓度为100μmol·L-1时,配合物1和2对脲酶的抑制率分别为37.2%和81.5%,其中配合物2的IC50值为21.5μmol·L-1。分子对接研究表明配合物2与脲酶活性中心存在有效的作用力。 Two new Schiff base vanadium complexes containing acetohydroxamate ligands, [VⅢL1(HAHA)] (1) and [VⅤOL2(AHA)] (2), where L1 is the dianionic form of N,N'-bis(5-methylsalicylidene)ethane-1, 2-diamine, L2 is the monoanionic form of 2-{[2-(2-hydroxyethylamino)ethylimino]methyl}-6-methylphenol, HAHA and AHA are the mono-anionic and di-anionic forms of acetohydroxamic acid, have been synthesized and characterized by physico-chemical methods and single-crystal X-ray diffraction. The V atoms in the complexes adopt octahedral coordination. Thermal stability and urease inhibitory activities of the complexes were studied. The percent inhibition of complexes 1 and 2 at the concentration of 100 μmol·L-1 on Helicobacter pylori urease are 37.2% and 81.5%, respectively. Complex 2 has IC50 value of 21.5 μmol·L-1. Molecular docking study indicates that there form effective interactions between complex 2 and the active site of the urease. CCDC: 961635, 1; 961636, 2.
出处 《无机化学学报》 SCIE CAS CSCD 北大核心 2014年第3期640-648,共9页 Chinese Journal of Inorganic Chemistry
基金 辽宁省高校优秀青年人才支持计划(No.LJQ2011114) 南京大学配位化学国家重点实验室开放课题基金 国家自然科学基金(No.20901036)资助项目
关键词 席夫碱 乙酰氧肟酸 钒配合物 晶体结构 脲酶抑制剂 schiff base acetohydroxamate vanadium complex crystal structure urease inhibitor
  • 相关文献

参考文献28

  • 1Francisco S S;Urrutia O;Martin V.查看详情[J],Journal of the Science of Food and Agriculture20111569-1575.
  • 2Xiao Z P;Ma T W;Fu W C.查看详情[J],EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY20105064-5070.
  • 3Barros T G;Williamson J S;Antunes O A C.查看详情[J],LETTERS IN DRUG DESIGN & DISCOVERY2009186-192.
  • 4Louie A Y;Meade T J.查看详情[J],CHEMICAL REVIEWS19992711-2734.
  • 5Sumangala V;Poojary B;Chidananda N.查看详情[J],Medicinal Chemistry Research20132921-2928.
  • 6Tehrani K H M E;Sardari S;Mashayekhi V.查看详情[J],CHEMICAL AND PHARMACEUTICAL BULLETIN2013160-166.
  • 7Azizian J;Mohammadi M K;Firuzi O.查看详情[J],Medicinal Chemistry Research20123730-3740.
  • 8Willsky G R;Goldfine A B;Kostyniak P J.查看详情[J],Journal of Inorganic Biochemistry200133-42.
  • 9Orvig C;Caravan P;Gelmini L.查看详情[J],Journal of the American Chemical Society199512759-12770.
  • 10Messerschmidt A;Prade L;Wever R.查看详情[J],Biological Chemistry1997309-315.

二级参考文献22

  • 1DENGZhao-Peng(邓兆鹏) GAOShan(高山) ZHAOHui(赵辉) etal.Wuji Huaxue Xuebao,2007,:173-176.
  • 2Francisco S S, Urrutia O, Martin V, et al. J. Sci. Food Agr., 2011,91:1569-1575.
  • 3Xiao Z P. Ma T W, Fu W C, et al. Eur. J. Med. Chem., 2010,45:5064-5070.
  • 4Barros T G, Williamson J S, Antunes O A C, et al. Lett. Drug Des. Discovery, 2009,6: ! 86-192.
  • 5Louie A Y, Meade T J. Chem. Rev., 1999,99:2711-2734.
  • 6Bernhardt P V, Chin P, Sharpe P C, et al. Dalton Trans., 2007,30:3232-3244.
  • 7Bernhardt P V, Wilson G J, Sharpe P C, et al. J. Biol. lnorg. Chem., 2008,13:107-119.
  • 8Yaul A R, Dhande V V, Suryawanshi N J, et al. Polish J. Chem.. 2009.83:565-571.
  • 9Willsky G R, Goldfine A B, Kostyniak P J, et al. J. Inorg. Biochem., 2001,85:33-42.
  • 10Orvig C, Caravan P, Gelmini L, et al. J. Am.. Chem. Soc., 1995,117:12759-12770.

同被引文献134

引证文献8

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部